rts logo

Phathom Pharmaceuticals Inc (PHAT) Is Now En Route to Higher Prices

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is -30.67% lower on its value in year-to-date trading and has touched a low of $5.95 and a high of $19.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PHAT stock was last observed hovering at around $5.99 in the last trading session, with the day’s loss setting it -0.36%.

Currently trading at $5.63, the stock is -17.25% and -27.81% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.06 million and changing -6.01% at the moment leaves the stock -52.12% off its SMA200. PHAT registered -15.97% loss for a year compared to 6-month loss of -50.74%. The firm has a 50-day simple moving average (SMA 50) of $7.8644 and a 200-day simple moving average (SMA200) of $11.780125.

The stock witnessed a -30.67% gain in the last 1 month and extending the period to 3 months gives it a -67.68%, and is -14.18% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.79% over the week and 7.10% over the month.

Phathom Pharmaceuticals Inc (PHAT) has around 452 employees, a market worth around $384.96M and $26.27M in sales. Profit margin for the company is -1292.14%. Distance from 52-week low is -5.30% and -71.44% from its 52-week high. The company has generated returns on investments over the last 12 months (-109.14%).

The EPS is expected to shrink by -37.62% this year.

Phathom Pharmaceuticals Inc (PHAT) Top Institutional Holders

198.0 institutions hold shares in Phathom Pharmaceuticals Inc (PHAT), with institutional investors hold 118.42% of the company’s shares. The shares outstanding are 68.32M, and float is at 34.90M with Short Float at 40.70%. Institutions hold 109.27% of the Float.

The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 10.11 million shares valued at $104.13 million. The investor’s holdings represent 17.3189% of the PHAT Shares outstanding. As of 2024-06-30, the second largest holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with 7.46 million shares valued at $76.89 million to account for 12.788 of the shares outstanding. The other top investors are CARLYLE GROUP INC. which holds 3.5 million shares representing 5.9906% and valued at over $35.84 million, while INVESCO LTD. holds 5.3853 of the shares totaling 3.14 million with a market value of $32.38 million.

Phathom Pharmaceuticals Inc (PHAT) Insider Activity

The most recent transaction is an insider sale by Henderson Molly, the company’s CFO and CBO. SEC filings show that Henderson Molly sold 6,583 shares of the company’s common stock on Jan 21 ’25 at a price of $6.59 per share for a total of $43371.0. Following the sale, the insider now owns 93546.0 shares.

Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 21 ’25 that Nabulsi Azmi (Chief Operating Officer) sold a total of 7,886 shares of the company’s common stock. The trade occurred on Jan 21 ’25 and was made at $6.59 per share for $51957.0. Following the transaction, the insider now directly holds 0.23 million shares of the PHAT stock.

Still, SEC filings show that on Jan 21 ’25, Curran Terrie (President and Chief Executive) disposed off 19,109 shares at an average price of $6.59 for $0.13 million. The insider now directly holds 360,465 shares of Phathom Pharmaceuticals Inc (PHAT).

Related Posts